Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient

Rhea-AI Summary

Therapeutic Solutions International (TSOI) successfully administered JadiCells™ to a treatment-resistant epilepsy patient, resulting in remarkable recovery after 35 years of debilitating seizures. The treatment was conducted under the Right to Try Act based on preclinical data supporting JadiCells™ efficacy over standard therapies. The Company has filed a patent for JadiCells™ use in epilepsy and is advancing Phase III trials for COVID-19. TSOI has also treated patients with Chronic Traumatic Encephalopathy under FDA IND protocols.

Positive

• Successful treatment of epilepsy patient using JadiCells™, leading to no seizures in three months.
• Filed patent application for JadiCells™ in epilepsy treatment.
• Progressing well in Phase III trial for COVID-19.
• INDs granted for Chronic Obstructive Pulmonary Disease and Chronic Traumatic Encephalopathy.

Negative

• None.

Phase III Clinical Trial Company Uses Universal Donor Stem Cell to Suppress Brain Inflammation for Multiple Neurological Conditions

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today successful administration of JadiCells into a treatment resistant epilepsy patient resulting in a profound recovery.

The patient was treated under the Right to Try Act as a result of preclinical data demonstrating significant advantage of JadiCells™ compared to standard umbilical cord mesenchymal stem cells in the pilocarpine-induced animal model. The company has filed a patent application covering the use of JadiCells™ for treatment of epilepsy and associated conditions.

“The patient had a history of epilepsy since the age of 28, leading to a life of crippling seizures and severe chronic tinnitus. The patient preferred to live in darkness for years due to any form of sound triggering violent seizures. The patient reported that he had not seen a movie, read a book or stepped out of his home for 35 years. We treated this patient with four regimens of JadiCell stem cells. In the first follow-up on Day 3 after treatment, he was feeling better and had not suffered a single seizure. By Day 7, he was watching his first movie and had begun to read his first book in decades. As of Day 20, after treatment, he was actually building a concrete flower container in his backyard and has not suffered a single seizure in three months,” said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor on the filed patient.

JadiCells™ are subject of a Phase III trial that the Company is performing for treatment of COVID-19. Additionally, the cells have been granted IND numbers for chronic obstructive pulmonary disease¹, and for Chronic Traumatic Encephalopathy², for which the Company is working with the FDA to initiate clinical trials. The Company has also successfully treated 15 patients with CTE or COVID-19 under Right to Try and Emergency IND³.

“The difference between us and other biotech companies is our ability to rapidly translate scientific findings into preclinical studies and based on the preclinical studies to rapidly enter patient use in an efficient and ethical manner through the Right to Try Law,” said Timothy Dixon, President and CEO of the Company and co-inventor. “On behalf of Therapeutic Solutions International I am proud in congratulating Dr. Veltmeyer in not only the clinical aspect but also in leading the scientific collaborations and tests which provided the rationale and scientific basis for this new approach to treating drug resistant epilepsy.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Review of TSOI’s COPD Therapy Moves Forward With IND Designation (copdnewstoday.com)

2 Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell (prnewswire.com)

3 Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial | Business Wire

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005539/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What recent achievement has TSOI reported regarding epilepsy treatment?

TSOI successfully treated a treatment-resistant epilepsy patient with JadiCells™, resulting in a profound recovery.

What is the significance of the Right to Try Act for TSOI?

The Right to Try Act allowed TSOI to administer JadiCells™ to a patient based on promising preclinical data.

What are TSOI's plans for JadiCells™ in clinical trials?

TSOI is conducting Phase III trials for the use of JadiCells™ in COVID-19 treatment and has submitted IND applications for other conditions.

How has TSOI progressed with their patent application?

TSOI has filed a patent application covering the use of JadiCells™ specifically for the treatment of epilepsy and related conditions.